研究拟评价多周期(大剂量)177Lu-DOTA-EB-TATE肽受体放射性核素治疗(PRRT)用于神经内分泌肿瘤(NETs)的安全性和有效性。共32例NET患者,随机分为3组:A组(1.17 ± 0.09 GBq/周期); B组(1.89 ± 0.53 GBq/周期); C组(3.97 ± 0...
Treatment with 177Lu-DOTA-EB-TATE extended survival and reduced tumor size in a mouse model characterized by high somatostatin (SST) analogues uptake (SUVmax, 15.16 ± 4.34), but had no effects in a model with low SST analogues uptake (SUVmax, 4.8 ± 0.27). Conclusions: A novel SST ...
177Lu-DOTA-EB-TATE177Lu-DOTATATENeuroendocrine tumorTreatment Using 177Lu-DOTA-EB-TATE in Patients with Advanced Neuroendocrine Tumors (NCT03478358). URL: https://register.clinicaltrials.gov/prs/app/action/ViewOrUnrelease?uid=U0001JRW&ts=13&sid=S0007RNX&cx=y3yqv4...
Analysis of 177Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors. J Nucl Med. 2015; 56:505-511.Denoyer D, Lobachevsky P, Jackson P, Thompson M, Martin OA, Hicks ... D Denoyer,P Lobachevsky,P Jackson,... - 《Journal of...
Lu-177-DOTA-EB-TATEpeptide receptor radionuclide therapyneuroendocrine tumorsamino acid infusionRENAL UPTAKEINHIBITIONOCTREOTIDEPRRTPurposeKidney is considered to be one of the dose-limiting organs in peptide receptor radionuclide therapy (PRRT). Amino acid cocktail infusion has been applied to reduce ...
Lu-177-DOTA-EB-TATE doses of 1.89 and 3.97 GBq/cycle were effective in tumor control and more effective than 1.17 GBq/cycle.Liu, QingxingZang, JieSui, HuiminRen, JiakunGuo, HuaWang, HaoWang, RongxiJacobson, OritZhang, JingjingCheng, YuejuanZhu, ZhaohuiChen, Xiaoyuan...
Treatment Using 177Lu-DOTA-EB-TATE in Patients with Advanced Neuroendocrine Tumors (NCT03478358). URL: https://register.clinicaltrials.gov/prs/app/action/ViewOrUnrelease?uid=U0001JRW&ts=13&sid=S0007RNX&cx=y3yqv4doi:10.1007/s00259-019-04530-1...
Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE.doi:10.2967/JNUMED.120.248658Qingxing LiuJie ZangHuimin SuiJiakun RenHua GuoHao WangRongxi WangOrit JacobsonJingjing Zhang...